IDEAYA Advances Oncology Pipeline with Novel Inhibitors and Gilead Collaboration

IDEAYA Biosciences查看公司主页 is making significant strides in its precision medicine oncology pipeline with the nomination of new development candidates and a clinical study collaboration with Gilead Sciences查看公司主页. These advancements underscore IDEAYA's commitment to developing targeted therapeutics for cancers with specific molecular profiles.

IDE251: A Novel KAT6/KAT7 Inhibitor

IDEAYA Biosciences查看公司主页 recently nominated IDE251查看药品详情 as a new development candidate. This molecule is a potential first-in-class dual inhibitor targeting KAT6 (搜索)搜索该靶点 and KAT7 (搜索)搜索该靶点, which are implicated in certain types of cancer, including breast and non-small cell lung cancer (搜索)搜索该疾病 (NSCLC (搜索)搜索该疾病). Preclinical studies have demonstrated robust and durable anti-tumor activity in tumor models with 8p11 amplifications, a genetic anomaly present in approximately 15% of breast cancer (搜索)搜索该疾病 patients and 17.5% of squamous NSCLC cases. The company is preparing for an Investigational New Drug (IND) submission to the U.S. Food and Drug Administration (FDA) in 2025, contingent upon successful completion of ongoing preclinical and IND-enabling studies.

According to Yujiro S. Hata, President and CEO of IDEAYA Biosciences查看公司主页, the nomination of IDE251查看药品详情 is a significant milestone, marking the third development candidate this quarter and the eighth in the company's precision medicine oncology pipeline. Michael White, Ph.D., Chief Scientific Officer at IDEAYA, emphasized the molecule's potential to deliver superior anti-tumor activity compared to KAT6 (搜索)搜索该靶点 inhibition alone in preclinical models.

Collaboration with Gilead on IDE397 and Trodelvy

IDEAYA has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences查看公司主页 to evaluate the efficacy and safety of IDE397查看药品详情, its investigational, potential first-in-class, small molecule MAT2A (搜索)搜索该靶点 inhibitor, in combination with Gilead's Trodelvy查看药品详情® (sacituzumab govitecan-hziy), a Trop-2 directed antibody-drug conjugate (ADC), in methylthioadenosine phosphorylase (MTAP)-deletion non-small cell lung cancer (搜索)搜索该疾病 (NSCLC (搜索)搜索该疾病).

The prevalence of MTAP-deletion is estimated to be approximately 15% in NSCLC (搜索)搜索该疾病. Darrin Beaupre, M.D., Ph.D., Chief Medical Officer, IDEAYA Biosciences查看公司主页, stated, "We are pleased to broaden the ongoing evaluation of the potential first-in-class clinical combination of IDE397查看药品详情 and Trodelvy查看药品详情 to now include patients with MTAP-deletion NSCLC in our ongoing Phase 1 trial currently evaluating the combination in MTAP-deletion urothelial cancer (搜索)搜索该疾病."

IDE892: A Potential Best-in-Class MTA-cooperative PRMT5 Inhibitor

IDEAYA Biosciences查看公司主页 announced the development candidate nomination of IDE892查看药品详情, a potential best-in-class MTA-cooperative PMRT5 inhibitor. IDE892 was discovered through IDEAYA's iterative physics-based ligand design and optimization platform and has demonstrated exceptionally selective antiproliferative activity in MTAP-deleted tumor cell models and durable complete responses in combination with MAT2A (搜索)搜索该靶点 inhibitor IDE397查看药品详情 in challenging MTAP-deletion preclinical models. IND-enabling studies for IDE892 are ongoing to support an Investigational New Drug (IND) filing to the U.S. Food and Drug Administration (FDA) in mid-2025, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.

"We continue to expand our precision medicine oncology pipeline and are excited to nominate our 7th development candidate in IDE892查看药品详情, a potential best-in-class MTA-cooperative PMRT5 inhibitor. IDE892 advances our strategic objective to enable a wholly owned combination between the PRMT5查看药品详情 and MAT2A (搜索)搜索该靶点 mechanisms, to deliver potentially greater efficacy in MTAP-deletion solids tumors through this rational combination approach," said Yujiro S. Hata, President and Chief Executive Officer of IDEAYA Biosciences查看公司主页.